Why Every Longevity Founder Quotes TAM—and Why Serious Investors Care About SOM

As the longevity economy matures into an investable asset class, capital is shifting its attention from market size to enterprise value.

Spend enough time reviewing longevity investment decks and a familiar pattern quickly emerges. Almost every founder begins with the same proposition: the longevity economy represents one of the most significant investment opportunities of the twenty-first century. Depending on how its boundaries are defined, the addressable market extends far beyond biotechnology to encompass diagnostics, preventive healthcare, digital health, nutrition, wellness, hospitality, insurance, financial services, and increasingly, the built environment. Collectively, the opportunity is measured not in billions, but in trillions of dollars.

It is a compelling investment thesis because category-defining enterprises are rarely built around constrained markets. Every transformative industry has required founders capable of articulating a future that capital had yet to fully recognise, and TAM (Total Addressable Market) provides the language for expressing that scale of ambition. Yet sophisticated capital has always understood that market size alone does not determine investment outcomes. A large market creates potential, but enterprise value ultimately depends on where an organisation can establish a defensible position and how effectively that position can compound over time.

This distinction is becoming increasingly relevant as longevity enters a more disciplined phase of capital formation. Only a few years ago, much of the industry's focus was directed toward establishing longevity as a credible investment category. Today, dedicated longevity funds have emerged, institutional capital is increasingly evaluating the sector, and family offices are considering longevity alongside healthcare, biotechnology, and human performance as part of long-term strategic allocations. As the asset class matures, the conversation inside investment committees is beginning to move beyond whether the opportunity is sufficiently large and toward a more consequential question: where, within this expanding ecosystem, is economic value most likely to concentrate?

That is where TAM, SAM, and SOM become more than market-sizing terminology. They provide a progression from possibility to strategic ownership: TAM (Total Addressable Market) establishes the scale of the opportunity, SAM (Serviceable Addressable Market) defines the portion of that opportunity a particular enterprise is structurally equipped to address, and SOM (Serviceable Obtainable Market) begins to reveal how much of that addressable market the business can realistically secure. For sophisticated capital, that progression matters considerably more than the headline number on the first slide of an investment deck.

The Difference Between Participation and Ownership

Every emerging industry begins with imagination. Founders must articulate a future that does not yet fully exist, while investors must determine whether that future represents a structural transformation capable of supporting long-term value creation. Longevity has already crossed that first threshold. The market no longer needs to be convinced that ageing, healthspan, prevention, and human performance represent some of the defining opportunities of this century. The more consequential question is how economic value will be created within this expanding ecosystem.

History demonstrates that large markets rarely distribute value evenly. The internet transformed global commerce, cloud computing reshaped enterprise infrastructure, and artificial intelligence is redefining multiple industries; yet in each case, value concentrated among enterprises that established strategic control over critical layers of the ecosystem.

Longevity is unlikely to follow a different path. As the sector expands across therapeutics, diagnostics, consumer health, longevity clinics, and health-oriented living models, numerous companies will participate in the growth of the market. However, enduring enterprise value will accrue to those capable of building defensible positions—through proprietary capabilities, trusted relationships, data advantages, distribution ecosystems, or strategic infrastructure.

The distinction is fundamental.

Markets create opportunities.

Strategic ownership creates value.

From Market Size to Strategic Addressability

This is where SAM becomes particularly important. TAM establishes the outer boundary of an opportunity, but it says little about the market a particular enterprise is actually equipped to serve. A longevity company may sit within a multi-trillion-dollar economic landscape, yet its commercially relevant market could be considerably narrower once its technology, regulatory environment, geography, customer profile, distribution model, pricing architecture, and capital requirements are taken into account.

For investors, that narrowing is not a weakness. It is where the investment thesis becomes more credible. A clearly defined Serviceable Addressable Market demonstrates that a company understands the terrain in which it can realistically compete rather than relying on the scale of an entire emerging industry to support its valuation narrative. In a sector as broad and interconnected as longevity, the distinction is especially important because the path from scientific innovation to commercial adoption can differ dramatically across therapeutics, diagnostics, consumer health, hospitality, real estate, and human performance.

The more precisely an enterprise can define the market it is structurally capable of serving, the more meaningful the subsequent discussion around market capture becomes. SAM therefore represents the transition from industry opportunity to enterprise-specific opportunity. It is where the broad promise of longevity encounters the commercial realities of regulation, distribution, capital intensity, customer behaviour, and competitive positioning.

Why SOM Is Really About Strategic Position

SOM is often introduced as a market-sizing framework. In reality, sophisticated investors use it to assess something far more consequential: strategic position. Once the investment thesis has been established, the discussion moves beyond the size of the opportunity and towards the quality of the enterprise itself. Can this business establish a defensible competitive advantage? Does it possess proprietary capabilities that strengthen over time? Can its position improve as the longevity ecosystem expands?

That question cannot be answered through arithmetic alone. It requires an assessment of competitive architecture: proprietary technology, intellectual property, data advantages, regulatory credibility, distribution, brand trust, strategic partnerships, switching costs, network effects, and the operational capabilities required to convert scientific or technological advantage into commercial scale. A company operating within a trillion-dollar market may still struggle to create meaningful enterprise value if its position remains vulnerable to competition. Conversely, an enterprise addressing a narrower segment may generate substantial value if its strategic advantages strengthen as adoption grows.

For longevity companies, this distinction is particularly consequential because the sector is inherently interconnected. Scientific capability may establish an initial advantage, but long-term leadership may depend equally on the ability to build trusted relationships, accumulate proprietary data, secure regulatory credibility, establish distribution, and connect multiple parts of the longevity journey into an integrated ecosystem. The strongest

SOM is therefore not necessarily the largest theoretical market share; it is the portion of the market that an enterprise can capture in a way that becomes increasingly defensible over time.

In that sense, SOM is less about participation than ownership. It asks not simply whether a company can enter a market, but whether it can establish a position from which economic value continues to accumulate as the category matures.

Where Longevity Will Create Its Greatest Value

As longevity evolves from an emerging scientific field into a multi-sector economic ecosystem, competitive advantage will extend well beyond breakthrough discoveries alone. Scientific innovation will remain the foundation of the industry, but the enterprises most likely to create enduring value will be those capable of translating scientific progress into scalable, trusted, and commercially sustainable platforms.

The next generation of longevity leaders will likely emerge from the convergence of multiple capabilities: proprietary biological data, clinical validation, regulatory expertise, trusted consumer relationships, strategic partnerships, and integrated ecosystems connecting prevention, diagnostics, healthcare, wellness, and human performance. This is where the structure of the longevity economy becomes particularly significant.

Unlike traditional healthcare categories, longevity does not belong to a single industry. Its value creation potential sits at the intersection of multiple sectors, creating opportunities for enterprises capable of connecting fragmented capabilities into coherent solutions.

Some companies may become the infrastructure layer supporting longevity innovation. Others may establish category leadership through scientific breakthroughs, personalised health platforms, or new models of longevity living. The defining question for investors will not simply be who participates in the longevity economy, but who is positioned to shape its evolution.

Beyond TAM and SOM

Every emerging asset class eventually reaches a point where imagination gives way to investment discipline. Longevity appears to be approaching that transition. The industry no longer needs to prove that the opportunity exists; the next phase will be defined by identifying which enterprises possess the strategic positioning, operational capabilities, and competitive advantages required to convert opportunity into enduring value.

Founders will continue to use TAM to communicate the scale of their ambition, and rightly so. Investors, however, will increasingly look through SAM to understand the market a particular enterprise can genuinely address, and through SOM to assess the portion it can realistically own. The three measures become meaningful not as a sequence of market-sizing exercises, but as a progression from macro opportunity to strategic position.

The enterprises that ultimately define the longevity economy will be those capable of moving beyond participation. They will translate scientific progress into durable business models, build assets and relationships that compound with scale, expand the boundaries of the markets they serve, and establish positions that become increasingly difficult to displace as longevity becomes embedded across healthcare, technology, hospitality, real estate, finance, and human performance.

For sophisticated capital, the question is therefore no longer simply how large the longevity economy could become. It is which enterprises will occupy the positions from which that growth can be converted into enduring enterprise value.

TAM defines the scale of the opportunity. SAM defines the terrain. SOM begins to reveal who can own it.

Because sophisticated capital does not simply invest in large markets.

It invests in enterprises capable of shaping them. Extending Horizons. Elevating Life.